ADC Therapeutics SA (ADCT) Misses Q3 EPS by 30c

ADC Therapeutics SA (NYSE: ADCT) reported Q3 EPS of ($0.65), $0.30 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $76.32 million versus the consensus estimate of $60.7 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c